Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, Arcadia Biosciences, Inc. reported revenue of $5M, down 3.7% year over year. Operating margin was -51.5% and net margin -48.1%, on a free-cash-flow margin of -97.6% with capital expenditure at 0.0% of revenue. Every figure is computed directly from RKDA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $5M | -51.5% | -48.1% |
| FY2024 | $5M | -72.3% | -139.5% |
| FY2023 | $4M | -137.0% | -313.9% |
| FY2022 | $7M | -188.8% | -207.3% |
| FY2021 | $7M | -524.0% | -216.2% |
How does RKDA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 23 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: PBR · VALE · SLB · FCX · NEM · HAL
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.